CPT Codes for Monoclonal Antibody COVID-19 Infusion
- broro75
- Nov 17, 2021
- 1 min read
On November 9, 2020, the U.S. Food and Drug Administration (FDA) issued an emergency use authorization (EUA) for the investigational monoclonal antibody therapy (bamlanivimab) for the treatment of mild-to-moderate COVID-19 in adults and pediatric patients with positive COVID-19 test results who are at high risk for progressing to severe COVID-19 and/or hospitalization.
On November 21, 2020, the FDA issued an EUA for the investigational monoclonal antibody therapy (casirivimab and imdevimab) administered together, for the treatment of mild-to-moderate COVID-19 in adults and pediatric patients with positive COVID-19 test results who are at high risk for progressing to severe COVID-19 and/or hospitalization.
Similar to bamlanivimab, casirivimab and imdevimab may only be administered in settings in which health care providers have immediate access to medications to treat a severe infusion reaction, such as anaphylaxis, and the ability to activate the emergency medical system (EMS), as necessary.
CMS identified specific code(s) for each COVID-19 monoclonal antibody product and specific administration code(s) for Medicare payment:
Q0239:
Long descriptor: Injection, bamlanivimab-xxxx, 700 mg
Short descriptor: bamlanivimab-xxxx
M0239:
Long Descriptor: intravenous infusion, bamlanivimab-xxxx, includes infusion and post administration monitoring
Short Descriptor: bamlanivimab-xxxx infusion
Q0243:
Long descriptor: Injection, casirivimab and imdevimab, 2400 mg
Short descriptor: casirivimab and imdevimab
M0243:
Long Descriptor: intravenous infusion, casirivimab and imdevimab includes infusion and post administration monitoring
Short Descriptor: casirivi and imdevi infusion
If you purchase product 1, you will be able to get $50 off.
If you purchase products 1 and 2, you will be able to get 100 off.
If you purchase products 1, 2, and 3, you will be able to get $ 150 off.
Click
Take the QUIZ to see how well you know your body:
Comments